SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Human Genome Sciences, Inc. (HGSI)
An SI Board Since March 1996
Posts SubjectMarks Bans Symbol
1127 105 0 HGSI
Emcee:  Jeffrey Ogbar Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
752Human Genome Sciences Establishes New Subsidiary in Europe - Will Manage Clinicabob zagorin-1/23/2003
751Looks like HGSI, MLNM and a few other biotechs got hit at the close with some laj g cordes-1/17/2003
750well here's the other side of that opinion. all biotechs share prices are debob zagorin-1/14/2003
749Bob, Someone on the MF board asked me the same question that you did. Here'Steven Rachbach-1/14/2003
748<<why couldn't they buy a smaller bio with great research platform thakeokalani'nui-1/13/2003
747Bob, You asked, <<why couldn't they buy a smaller bio with great reseSteven Rachbach-1/13/2003
746thanks for very interesting post. question. why couldn't they buy a smaller bob zagorin-1/13/2003
745This is a copy of a post I put on the Yahoo board. For the last few years, I haSteven Rachbach-1/13/2003
744zacks.com today. "...Human Genome Sciences, Inc. (NASDAQ: HGSI) is a pharmbob zagorin-1/9/2003
743Human Genome says Q4 in line with consensus ROCKVILLE, Md. Jan 6 (Reuters) - Hubob zagorin-1/6/2003
742ROCKVILLE, Md., Jan. 6 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nanigel bates-1/6/2003
741Human Genome Sciences Invites Investors to Listen to Webcast Of Presentation at bob zagorin-1/2/2003
740ROCKVILLE, Md., Dec. 3 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nanigel bates-12/3/2002
739Human Genome Sciences Reports Results of Preclinical Studies of Albuleukin(TM) abob zagorin-11/11/2002
738Biotech head blames big pharma for drug drought By Ben Hirschler LONDON, Nov 8 bob zagorin-11/10/2002
737Genomic Medicine Primer: First in a series from yesterday's New England JouSteven Rachbach-11/7/2002
736Addendum: I just examined the poster (with a magnifying glass) provided by HGSI Steven Rachbach-11/6/2002
735hgsi.com In general, I was impressed with the results of the study. At relativSteven Rachbach-11/6/2002
734Bob, HGSI's mission is to develop genomically derived drugs and their albumSteven Rachbach-11/5/2002
733correct me if i'm wrong. based on this q, hgsi has 1.55b minus .5 in debt dubob zagorin-11/5/2002
732I will confine my remarks to the KGF-2 for venous ulcer trial. The rest of theSteven Rachbach-10/30/2002
731ROCKVILLE, Md., Oct. 29 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nnigel bates-10/29/2002
730The day of the Sterling call last week, B of A hosted a c.c. for HGSI's CFO Steven Rachbach-10/24/2002
729Death Domain Containing Receptor-4 (DR4) Jian Ni, Craig A. Rosen, et. al. HumanMike McFarland-10/21/2002
728<i>Human Genome Sciences holds patents on 103 human genes, including thoseMike McFarland-10/20/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News